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Brain metastasis is a common and severe complication arising in up to 40 % of cancer 
patients. The prognoses for patients with brain metastases are dismal, with a median treated 
survival of around 10 months. Treatment of brain metastases is mostly limited to surgery and 
radiotherapy, as an intact blood brain barrier (BBB) effectively protects smaller tumors from 
chemotherapeutic agents. This means that even if there would be effective chemotherapy 
treatment regimens for metastases elsewhere in the body, brain metastases would not be 
affected by such strategies until late stages of cancer development, when the BBB is 
disrupted. 
The prevalence of metastatic melanoma has been increasing steadily the last years accounting 
for 10 % of all brain metastatic cancers. Advanced stage melanoma patients are commonly 
treated with targeted inhibitors, such as vemurafenib (a small molecule inhibitor, tailored to 
have a higher affinity to the mutated BRAF kinase). However an intact BBB then prevents the 
brain metastases from being affected by vemurafenib as well as most chemotherapeutic 
agents. 
Based on this a novel BBB permeabilizing peptide was of great interest for the work done in 
this thesis. The peptide is a combination of the low density lipoprotein receptor binding 
domain of ApolipoproteinE, and a 16 Lysine tail, which was named K16ApoE. 
In this study the in vitro mechanisms of K16ApoE was studied. Thereafter the ability of 
opening the BBB by the peptide was investigated, followed by a pilot study combining 
vemurafenib and K16ApoE in a small animal tumor model.  
Cell lines exposed to K16ApoE showed a high degree of cytotoxicity at prolonged exposures 
of high doses, by affecting cell viability and causing lytic cell death. However lower doses 
were in general tolerated by the cells. Scanning electron microscopy showed that the peptide 
caused damages to confluent endothelial cell monolayers likely by inducing lytic cell death. 
In contrast transmission electron microscopy showed the peptide did not affect cell-cell 
junctions.  
DCE-MRI on mice after intravenous administration of 200 µg of K16ApoE showed that the 
BBB was opened at already 10 minutes after injection, and was permeable at least 2 hours 
after injection. In animals given 100 µg of peptide the BBB was also permeabilized 10 
minutes after injection of the peptide. 
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The pilot treatment study using the xenograft mouse model for brain-metastatic melanoma, 
indicated a treatment effect when co-administering the peptide and a chemotherapeutic agent. 
The promising results of this study indicate the potential value of K16ApoE as a therapeutic 
strategy in brain metastatic cancers. Following this study full scale pre-clinical studies will 
follow, and based upon those the peptide may move forward towards clinical safety studies, 


























1.1 Skin cancer and melanoma 
The three types of skin cancers are squamous cell carcinomas (SCC) derived from the 
squamous cells of the epidermis, basal cell carcinomas (BCC) derived from the basal cell 
layer of the epidermis and malignant melanomas (hereafter called melanoma) derived from 
the melanocytes of the epidermis (Figure 1.1) [1]. 
Melanomas are caused by uncontrolled proliferation of melanocytes (Figure 1.1), the pigment 
producing cells of the skin. Melanomas tend to be heavily pigmented, but may also come in 
amelanotic (unpigmented) versions [2]. 
Melanomas most commonly arise in the skin (epidermis), but may also arise in oral or 
anogenital mucosal surfaces as well as the eyes, and anywhere melanocytes are found [3]. 
               
Figure 1.1: Schematic illustration of the skin, showing the position of melanocytes, where they are most 
commonly found, at the bottom of the epidermal layer of the skin. Figure by Terese Winslow from the 
National Cancer Institute (cancer.gov) [4]. 
 
Although they constitute no more than 5 % of skin-derived cancers (US-statistics), cutaneous 
melanomas are by a wide margin the most lethal skin -cancers, making up 90 % of all skin 
cancer derived deaths [2, 5]. 




Superficially spreading melanomas are characterized by radial growth, Nodular melanomas 
are primarily nodular with aggressive vertical growth, and short or absent horizontal growth. 
Lentigo maligna melanoma is characterized by lentiginous (pigment spot) proliferation, most 
often seen in sun-damaged areas in elder individuals. Acral lentiginous melanomas are 
typically found in the palms of hands, foot-soles or under nails, and commonly display poorly 
circumscribed pigmentation pattern.  
Additional rarer subtypes include desmoplastic characterized by vertical scar-tissue like 
growth [6], amelanotic characterized by unpigmented melanocytic lesions and polypoid 
melanoma an outward growing variation of the nodular subtype [7]. Combined these 
constitute less than 5 % of all melanomas [2]. 
Melanomas show a high degree of heritability with 5-10 % of melanomas occurring within 
predisposed families [2]. 
 
1.2 Incidence and causes of melanoma 
The incidence of melanoma is correlated with increasing age, (Figure 1.2), which is believed 
to be due to accumulated mutations from a longer lifespan [8]. 
 
Figure 1.2: Age distribution of new melanoma cases in the United States. The median age at diagnosis of 
melanoma in the U.S. was found to be 63 years [8]. Figure adapted from National Cancer Institute: SEER 
Cancer Fact Sheets (cancer.gov). 
 
The incidence rates of melanomas are highest in nations with traditionally paler complexions, 
(Figure 1.3). Countries with predominantly Caucasian populations show high incidence rates 
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[9]. A correlation with exposure to sun-light has led to UV-radiation being widely accepted as 




Figure 1.3: Worldwide incidence rates of melanoma of the skin, by country. Australia, USA, Canada, 
Western Europe (including Norway), and South Africa being at the top of melanoma prevalence [10].  Figure 
adapted from World Health Organization; GLOBOCAN2012. 
 
Epidemiological surveys have also shown that the rate of melanoma incidences has risen over 
the course of the past years [2, 8, 11]. This is commonly attributed to an increased prevalence 
of sun-tanning (increased UV-light exposure), as well as an increase in more specific 
classification of tumors by site of origin (not reflecting an actual increase) and increased 
lifespans which in turn correspond to an observed increase in overall cancer-incidence. 
In the United States, where it is the 5th most common cancer [12], the incidence of melanoma 
increased significantly in the years 1975-2012, though with hardly any increase in mortality 
(7.9 and 2.1 per 100 000 in 1975, compared to 22.9 and 2.7 per 100 000 in 2012) [8]. 
 
Norway has one of the highest occurrences of malignant melanomas in the world, and the 
incidence rate is currently rising, with approximately 1500 new cases being diagnosed per 
year (approximate incidence rate 30 per 100 000). There has been noted a steady annual 
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increase of the rate since first measured  in 1953 (one year after the national cancer registry’s 
establishment (1952)) which was 1.9 per 100 000 for men and 2.2 per 100 000 for women 
[11].  
 
1.3 Mutations in melanoma development 
Cancer cells escape apoptosis and proliferate through the effects of acquired mutations, with 
regulatory pathways in some way altered. Desensitization to death-signals and apoptosis 
pathways, constitutive activation of growth signal pathways enables this aberrant behavior.  
There are several mutations that are known to be integral to melanoma progression, with 
certain mutations occurring in most melanomas. Mutations in BRAF, NRAS, PTEN, TP53, 
p16INK4A, MAPK1, PPP6C, RAC1, SNX31, TACC1, STK19 have been statistically linked 
to melanoma development through cancer cell genome analysis, exemplifying the 
heterogeneity of melanoma mutations. There are however certain mutations with significantly 
elevated frequencies in melanomas, such as mutations in the BRAF-kinase [13]. The BRAF-
kinase is a member of the Raf-kinase family, a growth signal transducing kinase of the 
MAPK/ERK pathway. Approximately 42 % of melanomas harbor an activating mutation in 
the BRAF-kinase, making it the most frequently mutated gene in in this form of cancer[14]. 
The most common such mutation is the substitution of Valine to Glutamic acid at position 
600 (V600E), accounting for between 70 & 90 % of activating mutations in BRAF. The 
second most common mutation is the V600K substitution. Both of these mutations render the 
kinase constitutively active, leading to increased growth and proliferation [14, 15]. This has 
led to the targeting of mutated BRAF in novel a treatment regimen, using a mutation specific 
inhibitor vemurafenib, designed to have higher affinity towards BRAF with a (V600) 
mutation, acting on both (V600E) and (V600K) mutations [16].  
 
1.4 Grading and staging of melanoma 
Grading and staging of cancer are the classifications of neoplasms according to their probable 
clinical aggressiveness, extent and spread, used for making prognosis and assigning 
treatments. Grading of cancers seek to estimate their aggressiveness and their malignancy, 
based on cytology of cells within a tumor, and is determined by studying the cytological 
appearance of the tumor cells [3]. Staging of cancers is based upon exploring the primary size 
of the lesions, the potential spread to regional lymph nodes and the presence or absence of 
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metastases. Staging is determined by imaging or exploratory surgery [3]. Different staging 
systems are used for different cancers, to specifically suit the characteristic behaviors of the 
different types of cancers. 
There are two main methods of staging melanomas in use; the TNM-method (T, primary 
tumor, N; regional lymph node involvement, M; presence of metastases) and the AJC method 
(Stages 0-IV, by size of primary lesion, regional lymph node involvement, and presence of 
metastases). Both staging methods are essentially the same, the differences lie in notation 
convention only. 
Staging of melanoma consists of melanoma-specific versions of the TNM and AJC staging 
systems which are general cancer staging systems [17]. 
 
Figure 1.4: The 5-year survival of melanoma patients by staging. “Localized” are tumors confined to the site 
of origin, “Regional” are melanomas that have spread to regional lymph nodes, but not further, and “Distant” 
are metastatic melanomas (spread beyond the lymph nodes). “Unstaged” are melanomas of unknown staging, 
i.e. were not staged [8]. Figure adapted from National Cancer Institute: SEER Cancer Fact Sheets 
(cancer.gov). 
 
Survival from melanoma drastically decreases with metastasis. The initial 5 year survival of 
melanoma, discovered in its earliest stages, (localized tumors) is high, over 90 %, but drops 
off significantly with regional spread, to approximately 60 % (regional lymph node 
involvement) and becomes very poor, less than 20 %, with distal spread (metastasis; distant 





1.5 Treatment of melanoma 
The general treatment of melanomas is surgery with excision of the primary lesion and 
surrounding healthy tissues in a margin of conventionally 2 centimeters [2]. 
Primary surgical treatment is known to be effective in 80-90 % of cases, when discovered in 
its early stages, i.e. prior to metastasizing, with only 10-20 % experiencing remission 
following surgery. 
Systemic chemotherapy has been the standard form of treatment for distal metastatic 
melanomas with limited success [11], with it commonly being considered chemotherapy-
resistant. General or systemic chemotherapies are the use of various cytotoxic chemicals for 
cancer therapeutic purposes. Largely these are substances that affect cells during cell-division, 
as cancer cells are characterized by abnormal proliferation, causing cell death through 
interfering with processes such as DNA-synthesis and repair or cytoskeletal rearrangement 
during mitosis [18]. However novel targeted therapies introduced in recent years have shown 
greater effect than systemic chemotherapy, by extending life expectancies measurably [11].  
Radiotherapy has been used in the treatment of metastatic melanoma with limited success, in 
skin and lymph node metastases, demonstrating that melanomas are responsive only to high 
doses of radiation [19]. Whilst melanomas are less sensitive to ionizing radiation than other 
cutaneous tumors, radiotherapy has been used to curative effect on skin lesions [20]. 
The use of target treatments such as the V600E mutated BRAF-kinas specific inhibitor 
vemurafenib (also known as zelboraf, or PLX4032) has proven to be effective [21], also 
against V600K mutated BRAF melanoma [14]. This kinase inhibitor was specifically tailored 
to have an increased affinity toward the V600E mutated form of the BRAF-kinase, and has 
been shown to induce growth arrest and apoptosis in melanoma cell cultures [22]. However 
resistance to the drug is known to develop after prolonged treatment, with 20 % of tumors in 
xenografted mice developing resistance after 56 days in one model. Intermittent treatment 
regimens have been proposed as a way to circumvent resistance development [14, 21, 23]. 
Recently developed treatments using monoclonal antibodies including Nivolumab, 




Nivolumab acts through blocking ligand activation of the PD1 cell surface death-receptor on 
activated T-cells, a receptor which when activated is known to inhibit T-cell activity [24]. 
Pembrolizumab also acts upon the PD1 death receptor in much the same way as Nivolumab 
[25]. 
Ipilimumab acts through immune response potentiation. This is achieved by blocking the 
immune-inhibitory-  Cytotoxic T-lymphocyte associated Antigen 4 (CTLA-4), which is often 
up-regulated in cancer cells; allowing them to escape immune system mediated responses, 
enabling cytotoxic T-lymphocytes (CTLs) to act upon the cancer cells [26]. 
 
1.6 The metastatic process 
Metastases may be defined as secondary occurrences of tumor cells, distant from the primary 
neoplasm. The presence of metastases characterizes more than anything else a neoplasm as 
being malignant. The dissemination of malignant tumor cells happens by one (or more) of 
three routes; seeding of a cavity: when neoplasms invade a natural body cavity such as the 
ovaries, lymphatic spread or hematogenous spread [3]. Vascular spread gives metastases in 
more distal organs, hematogenous spread being thought the only way for brain metastases to 
occur [27].  
The steps of the metastatic process are migration, intravasation (entering vessels), transport, 
extravasation (leaving vessels) and metastatic colonization. The first and last of these steps 
are considered the rate limiting steps in the metastatic process. In order to migrate cells must 
break free from cell-cell adhesion (mediated by cadherin and integrins). The tumor cells 
penetrate the extracellular matrix (ECM) and stroma, by releasing various proteases (serine 
proteases and matrix metalloproteases predominantly). Intravasation, infiltration of the blood 
or lymphatic vessels, requires several steps, beginning with the attachment of cancer cells to 
the stromal face of the vessel followed by degradation of basement membrane in the case of 
blood vessel infiltration and lastly trans-endothelial migration to pass between the endothelial 
cells of the vessel wall. Transport through the blood stream follows, with subsequent arrest 
and extravasation. The site of extravasation is determined by both the proximity of the organ 
to the primary site (first-pass organ) and the propensities of the cancer, cancer cells 
preferentially metastasize to different organs depending on primary site. During extravasation 
the cells must first arrest in the capillary bed of the secondary organ and then cross the 
endothelium of the vessel wall and into the parenchyma. Selectin-family adhesion molecules 
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(especially E-selectin), amongst others (e.g. integrins), are implied in the adhesion to vessel-
endothelium. Notably selectins are differentially expressed in different organ-vasculatures, 
this probably lending to the preferences of metastasis by cancer origin. E-selectin is also 
implicated in the signaling cascade involved in trans epithelial migration. After crossing into 
the surrounding stroma, the cancer cells may establish and proliferate, giving rise to a novel 
tumor at the site. When grown past a certain size, the tumors will commonly also begin blood-
vessel formation (by angiogenesis, vasculogenic mimicry or vasculogenesis) to maintain its 
nutrient supply [28]. 
The epithelial to mesenchymal transition is of great importance in the metastatic process 
(specifically migration and intravasation) for epithelial derived cancers. The epithelial to 
mesenchymal transition (EMT), is the process wherein an epithelial cell (or cells) loses its 
epithelial like characteristics and assumes the characteristics of a mesenchymal cell, giving 
enhanced invasive and migratory properties as well as reduced susceptibility to apoptotic 
signals. The process normally occurs within embryonic development and organogenesis but is 
subverted during chronic inflammation and neoplasia [29]. 
 
Figure 1.5: The epithelial to mesenchymal transition (EMT), with (left to right) progressive loss of epithelial 
characteristics (phenotype, reorganization of cytoskeleton degradation of cell-cell adhesion proteins and 
changes in protein expression) and gain of mesenchymal characteristics. Figure adapted from Kalluri & 
Weinberg 2009 [29]. 
 
Brain metastasis is governed by predominantly two factors: the high blood flow of the brain, 
constituting 15-20% of total blood volume in the body in a resting state, and the propensity of 
certain cancers toward brain invasion, where cancers of certain origins are much more 
inclined toward brain metastasis. Whilst brain metastases may spread to any region of the 
brain in principle, size of areas and vasculature circumference places limits to where cancer 
cells most typically spread, with 85% of metastatic spread occurring in the cerebral 
hemispheres [27]. Following the formation of brain metastases, after cells have come to arrest 
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in the brain capillary bed and extravasated across the blood brain barrier (BBB), mediated 
mainly by genes HBEGF, COX2 and ST6GALNAC5 as well as integrin activation, into the 
brain parenchyma, the novel secondary tumor may either grow along the preexisting 
vasculature (called vascular co-option) or initiate angiogenesis to recruit its own vasculature 
(Figure 1.6) [28, 30].  
 
Figure 1.6: The brain metastatic process. Cells once disseminated from their primary tumor move along the 
vasculature until coming to arrest in the brain capillary bed, before extravasating through the BBB and 
forming secondary tumors within the brain. Following extravasation the tumor cells may either grow along 
the existing vasculature, or begin angiogenesis to form their own vasculature  [30]. Figure adapted from A.F. 
Eichler 2011. 
 
In the United States there are recorded approximately 200 000 new cases of brain metastatic 
cancers every year, 10 times the number of primary malignant brain tumors. 
Out of all systemic primary cancers it is estimated that up to 40 % of cancer patients will 
progress to have brain metastases [31]. 
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Figure 1.7: Primary sites of brain metastatic cancers by prevalence. The most common sites of origin are 
from lung cancer, breast cancer, melanoma and colon cancer.(Adapted from Bollig-Fisher et al. 2013) [31]. 
 
Varying estimates distribute brain metastatic cancers by the most common primary sites; 50-
60% from lung primary tumors, 20-30% from breast and 5-10% from melanoma (Figure 1.7). 
The prognosis for patients with brain metastatic cancers are dismal with median treated 
survival with microresection and radiotherapy at 9-10 months [31]. 
 
1.7 Treatment of brain metastases 
Administration of cortico-steroids is commonly done when patients have been found to 
harbour brain metastases. The mechanism of action whilst unclear is thought to be stabilizing 
the BBB to avoid vascogenic edema at sites of tumors. Anti-convulsants and anti-coagulants 
are also commonly administered to reduce the burden of symptoms, but without curative 
effect [32].  
Whole brain radio-therapy (WBRT) is used with some success, extending median survival by 
3-6 months, surgical excision in addition to WBRT extends median survival up to 10 months. 
Stereotactic radiosurgery also improves upon survival, increasing median survival up to 10 
months, though the damage done by high radiation doses limits the application to low 
numbers of metastases, and radiation induced necrosis is difficult to distinguish from tumor 
derived necrosis in clinical MRI. Chemotherapeutics are not commonly used against brain 
metastases until radiotherapy and surgery have been exhausted as possibilities [32], as the 
intact BBB effectively protects small-size tumors from most drugs [33]. Few 
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chemotherapeutics can cross an intact BBB, e.g. nitrosureas and high dose methotrexate, and 
these have been of limited efficacy. SRS in multiple instances, salvage SRS, with recurrence 
of cancer, have as of yet the most prolonged median survival, giving an average extension of 
7 months to survival. Combinations of WBRT and SRS were not found to be significantly 
better than WBRT alone, for patients with more than one metastasis, in a 2012 meta-analysis 
[32-34]. Stereotactic radiosurgery, where a high dose of radiation is administered to a targeted 
volume, have shown some improvement in localized control of tumors and overall survival in 
patients with melanoma brain metastases [35].  
 
1.8 The Blood Brain Barrier 
The Blood Brain Barrier (BBB) is a term used to describe the selective nature of the capillary 
vasculature in the brain towards diffusion. The constituents and structure of the BBB can be 
seen in Figure 1.7. This diffusion barrier excludes most substances from entering the brain 
parenchyma. The cellular components of the BBB are the endothelial cells of the vasculature, 
pericytes over these and astrocyte foot processes [36]. 
Tight junctions, and Adherence junctions between the endothelial cells of the brain 
vasculature limit the permeability of the brain parenchyma to water-soluble compounds from 
the blood-stream. Gap junctions are also thought to play a part among the BBB forming 
junctions, though evidence is not yet conclusive on the matter. Tight junctions are formed of 
trans-membrane proteins (e.g. occludins, claudins), and cytoplasmic proteins (e.g. zona 
occludens-1&2, cingulin) forming complexes linked to the actin cytoskeleton. Adherence 
junctions, responsible for cell-cell adherence of endothelial cells, constitute of (among others) 
cadherins (adherence points), catenins and actinin binding to the actin cytoskeleton. The brain 




                                 
Figure 1.8: A Schematic overview of The Blood Brain Barrier (BBB). The BBB consists of endothelial cells 
with tight junctions, and pericytes around the endothelial cells, with the foot processes of astrocytes and 
neurons latching on over. (Figure provided by Frits Alan Thorsen). 
 
The BBB demonstrates size, shape and charge exclusion of compounds, effectively excluding 
any compounds that are above 400Da in size or form more than 8 hydrogen bonds [39]. Of 
molecules smaller than the commonly assumed limit of 400Da, most are also found to be 
excluded, by the BBB, from entering the brain [40]. 
The selective nature of the BBB ensures that a large number of therapeutic compounds do not 
cross it, and are ineffective in treating conditions of the brain. For example brain metastases 
are notoriously difficult to treat clinically, as the BBB is disrupted late in brain metastatic 
development. 
 
1.9 Permeabilizing the BBB 
The selectiveness of the BBB severely inhibits delivery of larger treatment molecules 
(MW>400 Da) to brain tumors. Thus it has been a subject of some interest to identify 
strategies that would allow treatment agents to cross the BBB, either throughout the whole 
brain, or specifically at sites of disease. Several substances or procedures that permeabilize 
the BBB have been discovered, and in the following a few are mentioned: 
Receptor expressions applicable as a target for selective treatment regimens were found for 
breast carcinomas. In a murine model, localized expression of the receptor Tumor Necrosis 
Factor Receptor 1 (TNFR1) was found to be inducible through administration of Tumor 
24 
 
Necrosis Factor 1 (TNF1) at sites of brain metastases, which in turn allowed for localized 
permeabilization of the BBB [41]. 
Increases in serum bile acid concentrations have also been shown to increase BBB 
permeability in rats, through either bile duct ligation, or intravenous administration [42]. 
The venom of the Phoneutria nigriventer spider has been shown to cause acute BBB 
permeabilization and vascogenic edema in rats. The venom consists of several distinct toxins, 
and possibly one in isolation could prove to modulate BBB permeabilization [43]. 
Certain solvents such as DMSO, ethanol and glycerol, have been shown to permeabilize the 
BBB at g/kg levels in animal studies, though these have been found of limited use in a clinical 
setting [40]. 
Mechanical permeabilization through focused ultrasound has been under development for 
some time. This technique has applicability at local identified sites of disease, for example 
metastases grown to a detectable size by clinical imaging. Clinical trials using doxorubicin 
administered in conjugation with ultrasound contrast agents, by MRI guided focused 
ultrasound (ExAblate system) are ongoing. The safety of this treatment strategy is currently 
being evaluated prior to clinical efficacy studies [44-46]. Sonic methods also offer strategies 
to targeted release, by bursting microbubbles at a targeted site. In this way higher 
concentrations of a drug, e.g. chemotherapeutic agents, may be administered locally, with less 
systemic toxicity due a lesser overall dose [47].  
                              
Figure 1.9: Opening the BBB through application of focused, directed ultrasound to targeted site. A) The 
normal state of the BBB, with tight association of capillary endothelium preventing exchange with brain 
parenchyma. B) Energy released by focused ultrasound forces cell junctions apart, allowing for exchange 
between brain parenchyma and vasculature. Figure adapted from Hynynen et al. 2013 [48]. 
 
Hypertonic solutions of various substances (e.g. Urea, arabinose, lactamide, NaCl, and 
mannitol) have been shown to open the BBB through a mechanism presumed to be osmotic, 
causing cell shrinkage opening up the BBB allowing plasma soluble agents access to the brain 
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parenchyma. BBB-permeabilization using mannitol in a hypertonic fashion was successfully 
implemented as a part of a combinatorial treatment regimen against brain metastatic 
adenocarcinoma in humans [49].  
 
Figure 1.10: Hypertonic osmotic BBB permeabilization, a: depicts normal closed configuration of BBB, 
where most large molecules may not cross over to the brain parenchyma, b: depicts BBB as opened, due to 
cell shrinkage. Figure adapted from Bellavance et al. 2008 [49]. 
 
1.10 K16ApoE 
The Low Density Lipoprotein Receptor (LDLR) has earlier been shown to be involved in 
substances crossing over the BBB. Transcytosis was postulated to be the mechanism by which 
the LDLR moved substances over the BBB [50]. 
A synthetic peptide constructed of the receptor binding domain of ApolipoproteinE (ApoE) 
with a 16 lysine tail (K16) for nonspecific protein binding, was constructed by Sarkar et al, 
which showed BBB permeabilizing abilities. The peptide was originally tested with Evans 
blue dye and various therapeutic agents, where the original study noted passage into the brain 




                   
Figure 1.11: Opening of the BBB after intravenous treatment with K16ApoE. A) The top row shows effects 
of administration of  K16, ApoE compared to K16ApoE and difference between administering mixed with EB 
or immediately prior. B) The bottom row shows degree of leakage of EB into the brain parenchyma at 
different concentrations of K16ApoE. K16: 16 Lysine peptide, ApoE: ApolipoproteinE receptor binding 
domain, EB: Evan`s Blue dye.  Figure adapted from Sarkar et al. 2011 [52]. 
 
1.11 Models to Study Melanoma Progression 
 
1.11.1 In Vitro Models 
Culturing cells in vitro offers an ideal way for rapidly screening compounds for possible 
clinical efficacy as well as making naive observations about expression and growth of a 
specific cell type. The drawbacks of the approach includes a lack of interactions between 
microenvironment and cells, as well as immune mediated responses and other physiological 
parameters being mostly/completely absent.  
There are various strategies to culture cells, ranging from simplistic monolayer growth, to 
more complex 3 dimensional approaches. 
 
1.11.2 In Vivo Models (Xenografts) 
In Vivo Cancer Metastasis Models 
Of the animal models used to study the development and progression of cancers, two main 
categories exist: syngeneic models; where animal cancer cells are implanted into the same 
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type of animal (usually rats or mice), and xenograft models; where immune-compromised 
animals (mice or rats) are implanted with human cancer cells. Genetically engineered animal 
models where inserted somatic mutations lead to cancer predisposition, are commonly 
counted as variants of the syngeneic models. Models where tumor cells are injected into the 
blood stream are counted as ectopic, and models where cancer cells are implanted in the organ 
of origin as orthotopic [53, 54]. 
The discovery and selective breeding of B-cell and T-cell deficient animals have resulted in 
the development of numerous xenograft models. Mouse models are the most commonly used, 
exemplified in the Non Obese Diabetic Severely Combined Immunodeficiency (NOD/SCID) 
mice. Xenografts are developed from cultured biopsies that are introduced into the animals, 
where the take rate is usually high. The benefit of these models are the ability to specifically 
select the human cancer one wishes to study, and that these cells can be expected to behave 
similarly to as what they would in humans. The xenografts may be easily treated with drugs in 
for instance screening experiments and the results are more transferable to a clinical setting, 
e.g. when developing treatment regimens, compared to syngeneic models 
There are several limitations to the use of immunodeficient and mice models in general. This 
is due to the fact that the animals have a weakened immune system, interactions with which 
are foregone in these models, and most immune mediated treatments are thus inapplicable as 
well. The fact that mice whilst being mammals are evolutionarily quite removed from 
humans, also limits the direct applicability of results [53-55]. 
Animal brain metastasis models 
The need for models to study brain metastasis in vivo is obvious, and several animal models 
using mostly immunocompromised animals and human xenografts, have been established. 
The progression of tumor growth in the animals were found to be closely similar to what had 
been observed clinically in patients, which was taken as a sign of their applicability and value 
[53].  
 
 1.12 Imaging 
1.12.1 Fluorescent microscopy & time-lapse microscopy 
Light microscopy is a method of using elemental concepts of optics to focus light beams from 
samples in order to view the samples at greater magnification. 
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Fluorescence microscopy, is based on the physical phenomena called fluorescence. 
Fluorescence being the reemission of light of longer wavelengths after absorption of light 
with a characteristic wavelength(Figure 1.12) [56]. 
The discovery of biological fluorochromes, initially Green Fluorescent Protein (GFP), has 
found wide usage in biochemical and medical research [57, 58].  
The application of fluorochromes in what is called fluorescent microscopy has yielded a large 
variation on techniques exploiting the effect. The ability to attach visibly detectable tags to 
proteins or other cellular components allows for the study of intracellular positions as well as 
expression levels. 
 
                             
Figure 1.12: The physical process of fluorescence. Excitation of electron to higher energy level (shell) by 
photon of certain wavelength and subsequent emission, or de-excitation, wherein the electron returns to its 
original energy level with characteristic wavelengths of light corresponding to the energy difference being 
released. Figure adapted from University of Tennessee, Astrophysics Lecture notes [59]. 
 
Modern light microscopes are commonly conjugated with mercury lamps and light filtering 
systems. This allows them to expose a sample to specific wavelengths of light, as well as 
observing specific wavelengths alone, by also applying filters to detectors. As the 
wavelengths needed for excitations are different from those emitted by the subsequent 
emissions, only emitted light from fluorochromes will be visible in such a setup [56].  
Time-lapse microscopy is merely the application of automated image acquisition to an 
existing microscopy/imaging technique, yielding a series of acquisitions from the same 
location(s) at several time points. 
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1.12.2 Electron Microscopy 
Electron microscopy are the techniques of using accelerated electrons as the source of 
illumination in microscopy, made favorable by the smaller wavelengths of electron beams, 
comparative to the photon wavelengths of light. This allows for far greater resolution 
compared to light-microscopy. The electron microscope consists of an electron gun (filament 
to which a high voltage is applied), a cathode directing electrons toward and through the 
sample, magnetic coils acting as lenses (focusing and narrowing the electron beam) and a 
detector system, all encapsulated in a vacuum (needed to avoid the electrons interacting with 
anything other than the sample). The two basic types of electron microscopes are the 
Transmission Electron Microscope (TEM) and the Scanning Electron Microscope (SEM) 
(Figure 1.13) [60]. 
 
 
Figure 1.13: The two modes of electron microscopy; Transmission Electron Microscopy (TEM) and 
Scanning Electron Microscopy (SEM) compared to their predecessor light microscopy. TEM is based upon 
the attenuation of the electron beam through the sample, whilst SEM is based on secondary electrons from the 
surface of the sample. Figure adapted from Dr. Huvin Ganga [61]. 
 
Scanning Electron Microscopy (SEM) 
The Scanning Electron Microscope generates images of the (3D) surfaces of samples, by 
scanning a focused electron beam over the surface of an electrically conductive specimen (this 
is achieved by coating the specimen, typically with Gold or Palladium). This mode is not 
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homologous to conventional optical microscopy, but images are reconstructed from signals 
generated from secondary electrons, with brightness of a pixel corresponding to the number of 
secondary electrons generated form the surface of the sample [60]. 
Transmission Electron Microscopy (TEM) 
The transmission electron microscope was the first electron microscope developed and is 
homologous to the light microscope in its mode of operation. The electron beam behaves 
much the same way as light would due to the wave nature of particles. In TEM focused 
electron beams are directed through the sample, with brighter regions in the image 
corresponding to less obstruction of the electron beam by the sample. The use of TEM 
requires the samples to be finely sliced, dyed with metals, and only allows one to view small 
areas at a time, but at much greater resolution than SEM [60]. 
 
1.12.3 Magnetic Resonance Imaging (MRI) 
The NMR signal 
Nuclear Magnetic Resonance, the physical phenomena upon which NMR-spectroscopy and 
MRI are based, is the absorption and reemission of electromagnetic radiation by nuclei in a 
magnetic field. This is due to the fact that all isotopes with uneven proton and or neutron 
numbers have, due to the unpaired spin, a net magnetic moment. When in a strong magnetic 
field, the isotope has a resonance frequency (ω0) called the Larmor frequency, proportional to 
the magnetic field strength (B0) and its gyromagnetic ratio (γ: a physical constant). 
𝜔0 =  𝛾𝐵0 
Out of all the isotopes in a voxel (volume unit) a few more will align with the magnetic field 
(parallel) than against (anti-parallel), due to this being energetically slightly more favorable. 
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Figure 1.14:  The proton spin analogized as a bar magnet and the orientation of proton spins within a 
magnetic field B0, assuming parallel and anti-parallel states exemplified. (Figure adapted from (i) Frits 
Thorsen, (ii & iii)  M. Puddephat [62]). 
 
This small inequality of distribution, which is also proportional to field strength, is what gives 
an observable signal. The energy difference can be summarized as (where ΔE is the energy 
difference, ħ is Planck’s constant/2π, γ the gyromagnetic ratio, and B0 the magnetic field 
strength): 
∆𝐸 =  𝛾ħ𝐵0 
The resonance effects can be viewed as the spins being flipped out of alignment with the 
magnetic field. Having been disaligned the isotopes move in a rotating manner, called 
precession, back towards equilibrium, i.e. in alignment with the magnetic field. 
The signal in NMR and MRI is generated by the induced magnetic flux resulting from the 









Figure 1.15: A free induction decay signal, where the amplitude, decreases in an exponential manner with 
time. [62] (Figure adapted from M. Puddephat). 
 
The NMR-signal is constituted by two exponentially decaying processes, T1 and T2 
relaxation. These are: The loss of magnetization in the longitudinal direction, or spin-lattice 
relaxation which is the return of the net magnetization to the direction of the magnetic field. 
The loss of magnetization in the transverse plane, or spin-spin relaxation (orthogonal to the 
magnetic field) which is the dephasing of spins, which had aligned at the time of excitation. 
These are commonly denominated as Mz and Mxy. T1 is the time constant where net 
magnetization has recovered to 63 % of its initial value in the longitudinal direction and T2 
the time constant at which magnetization in the transverse direction has decayed to 37 %. 
Spin-lattice relaxation is caused by the return of the net magnetization vector to the 
equilibrium position, whilst spin-spin relaxation is the dephasing of the spins which had 
aligned in-phase at time of excitation by microscopic effects and inhomogeneities. 
The T2 relaxation is always shorter than the T1 relaxation, significantly so in vivo. 
The most commonly used elemental isotope for clinical scanning is the Hydrogen 1H isotope 
(the most common isotope of hydrogen), which has benefits in both ubiquitous presence in 
tissues as well as having the strongest NMR signal of all known isotopes [63-66]. 
 
Magnetic Resonance Imaging (MRI) 
Due to uneven distribution of protons and differing magnetic microenvironments around 
them, a spatially encoded 1H NMR signal allows for differentiation of structures and tissue 
types. This is called Magnetic Resonance Imaging (MRI) [67]. 
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MRI systems have additional magnets, inducing field gradients in z (parallel to magnetic 
field) and x,y directions (transverse plane), this is used to allow for spatial encoding of the 
resulting signal. 
The application of a gradient in the z-direction, alters the resonance frequencies along the 
gradient, allowing for “slice-selection” i.e. choosing a slice of a certain position and width 
(width given by the gradient strength and RF-bandwidth) wherein to excite protons. This 
gradient is applied at the same time as the excitation RF-pulse. 
The application of the phase encoding gradient is applied right after the slice selecting 
gradient and by altering their precession speed relative to the strength of the gradient felt by 
the protons along it. After the application of this gradient protons are again precessing at the 
same frequency, but now in different phases relative to their position along the gradient. 
Frequency encoding is the last step in spatial encoding and happens simultaneous to 
acquisition. A frequency encoding gradient is applied altering the frequencies of the protons 
precessions relative to their position along the gradient. 
 The raw-data from an MRI acquisition is a two dimensional time-domain signal, this 
representation is often referred to as k-space. The spatially encoded signal can be 
reconstructed into an image via a mathematical operation known as the Fourier Transform, 
which converts a time-domain signal into its frequency components. In order for a two 
dimensional image to reconstructed, a 2D Fourier Transform must be used [65, 66]. 
 
The Fourier Transform (in 1 Dimension): 






There are many variations in RF-pulse sequences and gradient settings used in MRI 
acquisition, allowing for more rapid acquisitions, different contrasts and different geometries 
of acquisition, as well as different reconstructions from k-space data. The variations in and 








                                
Figure 1.16: Illustration showing principles of the slice-selecting gradient, phase encoding gradient and 
frequency encoding gradient. A slice selection gradient, assures that different positions along it have different 
resonance frequencies, allowing to select a slice of a given width by choosing a bandwidth for the RF-pulse. B 
The phase encoding gradient alters the phase of protons such that their phase corresponds to their position 
along the phase encoding gradient. C The frequency encoding gradient applied at time of acquisition alters the 
frequencies of protons along it, thus encoding position along itself. [66] Adapted from Currie, S.  et al. 2013. 
 
Contrast enhancement and DCE-MRI 
Contrast enhancement in MRI is the use of several different compounds, called contrast 
agents, which affect the relaxation rates of their surroundings, leading to increase or decrease 
in signal. 
The relaxation rates of tissues are the characteristic deterioration of signal characterized by 
the time-constants T1 and T2. Relaxivity is the term used about the ability of a contrast agent 









0 + 𝑟𝑖[𝐶𝐴]; 𝑖 = 1𝑜𝑟2 where r stands for relaxivity and [CA] for the 
concentration of contrast agent [68]. 
This allows one to more clearly differentiate anatomical structures, and detect pathology such 
as brain tumors, by the leakiness of blood vessels within tumor tissue. 
Dynamic Contrast Enhanced – MRI or DCE-MRI is the use of a time series where images are 
sequentially taken of the exact same location over a set course of time whilst the contrast 
agent is administered. The measured change in T1 and T2 values is used as an indicator of the 
degree of perfusion of contrast agents within the region of interest. 
To model this a simple two-compartment model is used where the compartments are 
commonly divided into extracellular extravascular space (EES) and capillary vascular plasma 
space (Vp). 
 






= 𝐾1,2[𝐶𝑝(𝑡) − 𝐶𝑒(𝑡)] 
 
This general differential rate equation describes the rate of accumulation and wash-out of 
contrast agents in the EES, Ce is the concentration of contrast agents in EES, Cp is the 
concentration of contrast agents in Vp. 
Of particular use is the ability of this method to assess to what extent the BBB is open or 
leaking, with different kinetics observable in such a case [69, 70]. 
                  
Figure 1.17: Tofts two compartment model for contrast agent behavior over time. The rate constant K1,2 or 
Ktrans governs the movement of contrast into the extracellular extravascular space, and the rate constant K2,1 
describes the transfer of contrast agents back into the vasculature. Figure based upon Totfs et al. 1999 [70]. 
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1.12.4 Bioluminescence Imaging (BLI) 
There are several naturally occurring species that exhibit a phenomena called luminescence, 
wherein an enzymatic reaction of a special substrate produces visible light emissions. The 
most widely known such species is the firefly, the enzyme from which, amongst others, has 
also been adapted for the imaging technique known as bioluminescence imaging (BLI). 
The substrate-enzyme pair (of which there are several) is called luciferin and luciferase. 
This method allows for cells to be tracked in vivo (or in vitro) by adding the substrate or 
having the substrate produced in the cells themselves.  
The reaction can be simplified as follows for understanding the basic principle: 
Luciferin + O2 + ATP (luciferase) → oxy-luciferin + CO2 + AMP + diphosphate +visible light  
In-vivo BLI is usually conducted by injecting anaesthetized animals containing tumor cells 
bearing luciferase genes, with the substrate luciferin and imaging the animal using a detection 
system or photon counter for visible light, within a light-proofed container. 
The number of photons counted, corresponding to the number of reactions, by the detection 
system over a region of interest will be proportional to the number of cells expressing the 
luciferase enzyme in the region of interest (ROI). This indicates the presence of cells (above a 
certain threshold) and yields information on relatively how many cells are present in the ROI 
[71-73]. 
 
Figure 1.18: A typical setup of an optical imager used in Bioluminescence Imaging (BLI). The system has a 
light-proof imaging chamber containing the animal and a photon detecting system which feeds to an external 
computer, and gas anaesthesia required to keep the living animal immobilized. The system depicted is the 




2 Aims of this Study 
The main aim of this thesis was to study the in vitro and in vivo effects of a novel peptide 
K16ApoE, previously reported to open the blood-brain barrier. The sub-aims were: 
 To demonstrate by DCE-MRI that K16ApoE opens the BBB. 
 To study by DCE-MRI how long the BBB remains open after administration of 
K16ApoE. 
 To study mechanisms of action of K16ApoE in vitro. 
 To study treatment effects of vemurafenib on brain metastasis in vivo. 
 To study treatment effects of vemurafenib on brain metastasis in vivo after opening the 




















3 Materials and Methods  
3.1 In Vitro 
Cell lines used: 
H1_DL2: derived from secondary brain tumor (metastatic melanoma) from a 38 year old 
woman operated at Haukeland University Hospital. The cells have been transduced with GFP 
and firefly luciferase genes [54]. 
SV80: human lung fibroblast cell line, SV-40 transformed [from ATCC]. 
RBE4: Rat brain endothelial cell line, kindly provided by professor Aschner of Vanderbilt 
University. 
MDCKII: Madin-Darby canine kidney epithelial cell line, kindly provided by professor 
Yliperttula of the University of Helsinki. A version of this cell line was created during this 
study: MDCKII mcherry, which was transduced with the mcherry fluorescent protein. 
HUVEC: Human vascular endothelium cell line [from ATCC]. 
 
Flow-cabinet: All cell culture work, and preparations of injection solutions were done in a 














Medium and solutions: 
ALT-DMEM HUVEC medium 
450 mL Dulbeccos Modified Eagles 
medium (Sigma D5671) 
50 mL inactivated Fetal Bovine Serum 
(Fisher Scientific A15-043) 
10 mL 200mM L-Glutamine  
(Bio Whittaker BE17-605E) 
10 mL Penicillin/Streptomycin  
(Bio Whittaker DE17-603) 
16 mL non-essential amino acids (100X) 
(Bio Whittaker BE-114E) 
100 µL Plasmocin 25 mg/mL   
(Invitrogen) 





50 mL Fetal Bovine Serum  
(Fischer Scientific) 
50 mg Heparin Sodium Salt  (Santa Cruz 
203071) 
15 mg Endothelial Cell Growth Supplement 
(Sigma 2759) 
MDCKII medium RBE4 medium 
465 mL Dulbeccos Modified Eagles 
medium (Sigma) 
5 mL Penicillin/Streptomycin  
(Bio Whittaker) 
5 mL 200 mM L-Glutamine  
(Bio Whittaker) 




225 mL Hams F10 nutrient mix  
(Thermo Fisher Scientific) 
225 mL Minimum Essential Medium 
(MEM) 
(Thermo Fischer Scientific) 
5 µL Human recombinant Fibroblast 
Growth Factor ( ) 
50 mL Fetal Bovine Serum  
(Fisher Scientific) 
150 mg geneticin 
 
Trypsin PBS 
Trypsin EDTA 0.25 %  
(Bio Whittaker) 





Vemurafenib (PLX4032): BRAF(V600E) specific small molecule inhibitor. Purchased from 
Chemietek, Indianapolis, Indiana, USA. 
K16ApoE: The BBB permeabilizing peptide used in this study, was first produced by Dr. 
Gobinda Sarkar (Dept. of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MI, 
USA) thereafter by Senior Researcher Dag Erlend Olberg (Norwegian Medical Cyclotron 
Centre, Oslo) and delivered as a desiccated powder. The complete sequence of the peptide is: 
NH2-KKKK KKKK KKKK KKKK LRVR LASH LRKL RKRL LRDA-NH2 [52]. The 
molecular mass of the peptide is Mw=4521.79 the charge is 24 and the isoelectric point = 
12.85. 
 
Freezing solutions for cell lines: 
Freezing solution for H1_DL2 & SV80:  
Solution 1: 10 % FBS (Fetal Bovine Serum) in ALT-DMEM,  
Solution 2: 20 % DMSO in PBS. 
Freezing solution for H1_DL2 and SV80 cell lines: 1:1 Solution 1 & Solution 2.  
Freezing solution for RBE4 and MDCKII cell lines: Growth medium supplemented with 7.5 
% DMSO. 
Freezing solution for HUVEC cell line: Growth medium supplemented with 5 % DMSO. 
 
3.1.1 General Cell Culture Work 
 
H1_DL2 & SV80 cell lines maintenance: 
The cells were cultured in monolayers in cell culture medium, in filter capped cell culture 
flasks (Nalge Nunc International, Rochester New York USA) of sizes 25 cm2, 75 cm2 or 175 
cm2. The cells were kept in an incubator with 5 % CO2, 100 % humidity and 37
0C. The cells 
were passaged when confluent, for use, or maintenance (removal of superfluous cells). 
Passage was done by washing the cells with PBS (2, 3 or 4 mL PBS according to the size of 
the flask), followed by trypsinization of the monolayer (2, 3, or 4 mL Trypsin-EDTA) for 5 
min in the incubator. Then growth medium (3, 4, or 5 mL medium) was added to inactivate 
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the Trypsin. The resulting cell solution was then diluted to the appropriate concentration for in 
vitro experiments, or transferred (2-9 mL, as desired) to a new culture flask. 
RBE4 & MDCKII cell line maintenance: 
The cells were grown in collagen coated T75 culture flasks (Nunc) (7.5 µg/cm2 collagen; 10 
mL of 56.25 µg/mL type 1 rat tail collagen solution in PBS). The cells were grown to 80 % 
confluence before passage, with medium change every second day. Passage was done by 
washing the cells with PBS (3 mL PBS), trypsinization to dissolve monolayer (3 mL Trypsin-
EDTA) for 5 min in the incubator, and 4 mL was added to inactivate the Trypsin. The 
resulting cell solution was then diluted to appropriate concentrations for in vitro experiments, 
or transferred (2-7 mL, as desired) to a new culture flask. 
HUVEC cell line maintenance: 
The cells were cultured in monolayers in filter capped cell culture flasks T25, T75, T175 
(Nunc) in cell culture medium. The cells were kept in an incubator with 5 % CO2, 100 % 
humidity and 370C. The cells were passaged when confluent, for use, or maintenance 
(removal of superfluous cells). Passage was done by washing the cells with PBS (2, 3 or 4 mL 
PBS), followed by trypsinization of the monolayer (2, 3, or 4mL Trypsin-EDTA) for 5 min in 
the incubator. Then growth medium (3, 4, or 5 mL medium) was added to inactivate the 
Trypsin. The resulting cell solution was then diluted to the appropriate concentrations for in 
vitro experiments, or transferred (2-9 mL, as desired) to a new culture flask. 
Freezing procedure H1_DL2 & SV80: 
The cells were grown to confluence in a large culture flask (175 cm2). The cells were then 
washed with 4 mL PBS, trypsinized with 4 mL Trypsin for 5 min in the incubator, after which 
5 mL medium was added to stop trypsinization. The cell solution was then transferred to a 10 
mL tube and centrifuged at 900 rpm for 4 min, subsequently medium was removed and the 
pellet resuspended in freezing solution. The cells in freezing solution were then divided into 4 
cryotubes (pr. large flask), placed in a -800C freezer for 24 hours, before being transferred to a 
liquid nitrogen tank for prolonged storage. 
Freezing procedure for RBE4 and MDCKII: 
The cells were grown to confluence in a large (175 mm2) culture flask coated with collagen 
(7.5 µg/cm2). The cells were washed with 4 mL PBS, trypsinized for 15 min with 4mL 
Trypsin in the incubator, after which 5 mL medium was added to stop trypsinization. The cell 
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solution was then transferred to a 10 mL tube and centrifuged at 900 rpm for 4 min, the 
medium was removed and the pellet resuspended in freezing solution. The cells in freezing 
solution were then divided into 4 cryotubes (pr. large flask), placed in a -800C freezer for  24 
hours, before being transferred to a liquid nitrogen tank for prolonged storage. 
 Freezing procedure for HUVEC: 
The cells were grown to confluence in large culture flasks (175 cm2). The cells were then 
washed with 4 mL PBS, trypsinized with 4 mL Trypsin for 5 min in the incubator, after which 
5 mL medium was added to stop trypsinization. The cell solution was then transferred to a 10 
mL tube and centrifuged at 900 rpm for 4 min, the medium was removed and the pellet 
resuspended in freezing solution. The cells in freezing solution were then divided into 4 
cryotubes (pr. large flask), placed in a -800C for 24 hours, before being transferred to a liquid 
nitrogen tank for prolonged storage. 
Transfection of MDCKII with mcherry: 
 
 
Figure 3.1: pGreenFire, HIV-based lentiviral vector, used for viral vector mcherry transduction. (System 
Biosciences, Paulo Alto, California, USA). Figure provided by supplier. 
 
The cells were grown to partial confluence (ca. 40 %) in a small culture flask, before 2 mL 
medium containing pGreenFire lentiviruses containing mcherry was added. The 
manufacturing of the virus medium was performed by others in the lab, and was beyond the 
scope of this thesis. The cells were incubated in the virus medium for 24 hours at 370C and 5 
% CO2, before the virus medium was replaced with normal growth medium, and grown to 
43 
 
confluence before being passaged to a medium culture flask. Cells expressing red fluorescent 
protein mcherry were sorted by flow-cytometry (BD LSRFortessa, BD Biosciences, Franklin 
Lakes, NJ, USA). 
3.1.2 Resazurin-resorfin Cell Viability Assay 
A resazurin-resorfin viability assay was performed in order to assess the viability of cells post 
treatment with either vemurafenib, to establish its efficacy or K16ApoE to evaluate its 
cytotoxicity. The assay determines the percentage of a fluorescent metabolite converted (from 
resazurin to resorfin), as this metabolic activity is a measure of cell viability. 
The cells were seeded (4000 cells/100 µL per well) in 96 well-plates. 24 hours after seeding 
the cells, they were treated with different concentrations of vemurafenib (0.001 µM, 0.01 µM, 
0.1 µM, 0.5 µM, 1 µM, 5 µM, 50 µM or 100 µM) or K16ApoE (0.1 µg/mL, 1 µg/mL, 20 
µg/mL, 40 µg/mL, 60 µg/mL, 80 µg/mL, 100 µg/mL or 150 µg/mL). The following controls 
were also set up: DMSO-control at the same concentration as in highest vemurafenib dose, 
cells in only medium, and medium without cells (the vemurafenib experiments). Cells in 
medium alone and medium without cells (the K16ApoE experiments). 
72 hours after adding vemurafenib cells were treated for 4 hours (in incubator) with resazurin 
0.01 mg/mL (the vemurafenib experiments). 45 minutes after adding K16ApoE medium 
containing K16ApoE was replaced with fresh growth medium,  and cells were then treated for 
4 hours (in incubator) with resazurin 0.01 mg/mL (the K16ApoE experiments). Subsequently 
fluorescence at 560-590 nm was measured using a Wallack/Perkin Elmer 1420 VICTOR3 
plate reader (Perkin Elmer, Waltham, MA, USA). 
Statistics and plots were done using the Graphpad PRISM ™ software (v7.00, GraphPad 
software, La Jolla, CA, USA). 
 
3.1.3 Morphological light microscopy 
To asses morphological differences in H1_DL2 melanoma cell line cells treated with 
vemurafenib, light microcopy was performed. 
H1_DL2 cells were seeded at 105 cells per well in 2 mL medium in 6-well well-plates, 
thereafter allowed to attach and grow over 24 hours in incubator. After 24 hours medium was 
removed and 3 wells were treated with vemurafenib at a concentration of 50 µM in growth 
medium, the other half served as an untreated control group. 
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The cells were imaged using a NIKON TE2000 (Nikon, Tokyo, Japan) microscope at 24, 48 
and 96 hours post-treatment. 
 
3.1.4 Time-lapse fluorescence microscopy 
In order to assess membrane stability of cells treated with K16ApoE, time-lapse fluorescence 
microscopy of MDCKII cells transduced with fluorescent protein mcherry, and H1_DL2 
which already expressed GFP, was performed. 
The cells were seeded at 20-50,000 cells/500 µL per well in ibidi® µslide 4-well well-plates 
(ibidi GmbH, Martinsried, Germany), coated with 7.5 µg/cm2 for MDCKII cells, and without 
collagen for H1_DL2 cells, overnight to allow attachment.  
The cells were treated with varying concentrations (0, 80, 100 µg/mL) of K16ApoE diluted in 
growth medium and imaged using the appropriate color channel of the fluorescence 
microscope (NIKON TE2000), with one image taken every 30 seconds over the course of 1 
hour. 
The images were analyzed using the ImageJ software (National Institute for Health, Bethesda, 
Maryland, USA) with an ND2 (NIKON) file format plugin, converted to binary image using 
Otsu’s method [75] (in group variance minimization = inter-group variance maximization) 
and the ‘analyze particles’ function was used to quantify the results. 
 
3.1.5 Electron Microscopy 
Electron microscopy was used in order to ascertain morphological effects of K16ApoE on 
epithelial cell lines RBE4 and MDCKII. All EM proceedings were done with assistance by 
UiB Molecular Imaging Centre (MIC) staff, and all specialized reagents for EM were 
provided by MIC in conjuncture with EM-procedures. 
For electron microscopy the cells were seeded in the wells of 24-well plates (Nunc), collagen 
coated 7.5 µg/cm2, with 12mm Ø coverslips for SEM and without for TEM. Cells were 
seeded in 500 µl of growth medium containing approximately 4*105 cells. The cells were 
grown to complete confluence prior to treatment with the varying doses of K16ApoE (20, 40 
& 80 µg/ml). After 45 minutes the cells were fixed with 2.7 % Glutamic acid aldehyde (60 µl 
25 % solution added directly). The cells were subsequently washed 2 times with Sodium 
Cacodylate buffer 0.1 M, before being post fixated with OsO4 0.1 M in 0.1 M Sodium 
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Cacodylate buffer, then washed again 2X with Sodium Cacodylate buffer 0.1 M. The cells 
were the dried for 15 minutes in 30, 50, 70, 96, & 2x100 % ethanol, prior to SEM or TEM 
specific procedures. 
 
Scanning Electron Microscopy (SEM) 
Critical point drying was done on the cover slips for SEM, and then coated with 5nm Cd-Au 
alloy, using a JEOL JFC-2300HR  High Resolution Fine Coater (JEOL Ltd., Tokyo, Japan). 
SEM was performed with a Scanning Electron Microscope JEOL JSM-7400F (JEOL Ltd., 
Tokyo, Japan). 
 
Transmission Electron Microscopy (TEM) 
Cells for TEM were cast into Agar100 (Agar Scientific Ltd. Essex, UK) resin, first 1:1 
resin:100 % EtOH, hardened overnight at 370C, then empty gelatin capsules were embedded 
in the resin, pure resin added and incubated at 600C overnight, before capsules were filled 
with pure resin and solidified at 600C. The TEM samples were then sliced to the desired 
thickness with the REICHERT ULTRACUT S microtome (Leica AG, Wien, Austria). 






Figure 3.2: The electron microscopes used for this study. SEM: The Jeol JSM-7400F scanning electron 
microscope. TEM: The Jeol JEM-1230 transmission electron microscope. Both microscopes situated at the 
Molecular Imaging Centre core facility (University of Bergen). 
 
3.2 In Vivo 
Mice and Housing Conditions 
The mice used in the study were NOD/SCID Non-Obese Diabetic Severe Combined Immune 
Deficient mice, bred at the animal facility at Haukeland University Hospital.  
Mice were kept in groups of 2-4 in cages with woodchip bedding and enrichments, feed-
pellets and water provided ad libitum. 





Figure 3.3: The Bruker Pharmascan® 7T small-animal MRI used in this study. Connectors for animal bed 
water-heating and anesthesia (sevoflurane) visible. Animal bed and coils not mounted in picture. 
 
3.2.1 K16ApoE kinetics studies, DCE-MRI 
DCE-MRI was preformed using the 7 Tesla Bruker Pharmascan 70/16 (Bruker Biospin AG, 
Ettlingen, Germany) small animal MRI (Figure 3.3), with a 72mm quadrature transmit coil 
and mouse brain array receive coil, in order to evaluate the quality and duration of BBB 
permeabilization.  
K16ApoE was administered 200 µg in 100 µl PBS via tail-vein catheter (Figure 3.4A) over a 
duration of 60 seconds. Ominscan® contrast agent (Gd-diamide, GE Healthcare, Little 
Chalfont, UK) was administered at the time of scan, also by using a tail-vein catheter, 
connected to an automated syringe pump PHD2000 (Harvard Apparatus, Holliston, MA, 
USA). A bolus of 0.5 µmol/g (solution 0.1mmol/ml volume adjusted to animal weight) was 
injected over 20 seconds. 2*50cm catheters were used to reach animal inside scanner, dead-
volume: 30µl/50cm tubing. All animals were anesthetized with sevoflurane for injections and 
scans (5 % for induction and 2.5 % for maintenance) (Figure 3.4B). 
Control animals were administered 100 µL saline instead of K16ApoE (9 mg/mL, Fresenius 
Kabi AG, Bad Homburg, Germany) prior to DCE-MRI. 
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For the first few scans a T1 weighted DCE sequence with: TR=15ms, TE=2.1ms, FA=170, 
was used, obtaining 1500 images. Thereafter the DCE-sequence was shortened to obtaining 
900 images. The scan was initiated 15 seconds prior to bolus-injection of Omniscan contrast 
agent. The images were acquired with ParaVision v5.1 software, and DCE analysis was 
performed using the NordicIce v4.04 software (NordicNeuroLab, Bergen, Norway) on an 
offline workstation. Area under curve (AUC, the definite integral of the concentration time-
curve of contrast agent) and volume transfer coefficient (K1,2) were determined for a region of 
interest (ROI) encompassing the brain. For older scans with 1500 images, only the first 900 
were used in the analysis to be comparable to later scans. 
 
 
Figure 3.4: Tail vein injection setup and anesthesia vaporiser A) Mouse with tail-vein catheter inserted, lying 
on heating blanket. B) Sevotec 5 inhalation anesthetic vaporizer, (GE-Healthcare, Madison, Wisconsin, USA) 
sevoflurane inhalation system used for gas-anesthesia. 
 
3.2.2 Mouse Xenograft Model 
The mice were anaesthetized using 5 % isoflurane gas-anesthesia before cells were injected, 
(5*105 H1_DL2 cells suspended in 0.1 ml PBS), into the left ventricle using a 30G insulin 
syringe (Omnican, B.Braun AG Melsungen, Germany) guided by ultrasound. The mice were 
given 0.05 ml Buprenorphine hydrochloride (Buprenex, Cardinal Health, Elk Grove, CA, 




3.2.3 Pilot Treatment Experiment 
In order to assess potential clinical efficacy when treating brain metastases, xenografted mice 
were treated with either K16ApoE and vemurafenib, or vemurafenib alone. 
A group of 5 mice were injected intra-cardially with 5*105 H1_DL2 cells in 0.1ml PBS, and 
divided into two groups of treatment; three animals (2females, 1male) for combinatorial 
treatment with K16ApoE and vemurafenib, and two (1female, 1male) for treatment with 
vemurafenib alone. The treatment was started 9 days after tumor cell injection. 
K16ApoE diluted to 2mg/ml in PBS was administered intravenously at a volume of 100µl, 
corresponding to 200µg per animal, twice a week to the relevant animals. Animals receiving 
K16ApoE were anesthetized with sevoflurane during injections (% 5 for induction, and 2.5 % 
for maintenance).  Vemurafenib (14.7 mg/ml in 60 % DMSO and 40 % PBS) was 
administered intraperitoneally at a dose of 50mg/kg every weekday of the study to all animals. 
The animals were weighed twice a week through the entire pilot. 
 
Figure 3.5: Timeline of Pilot Study. 
 
3.2.3.1 BLI 
At week 4 the animals were imaged using BLI to confirm growth and presence of H1_DL2 
cells within the animals. 
The animals were injected with 150 mg/kg D-luciferin intraperitoneally and imaged 10 min 
post-injection using the Optix SX-470 small animal Optical imager (Advanced Research 
Technologies Inc. Saint Laurent, Canada). Imaging was done with animals in prone and 
supine position. Image acquisition and analysis was done using the Optix Optiview software 
v2.001. The animals were anaesthetized with sevoflurane in an inhalation system for the 




3.2.3.2 MRI (T1, T2, T1-contrast – anatomical sans) 
Mice were anaesthetized and maintained with sevoflurane during all scans (5 % for induction 
and 2.5 % for maintenance).  
T2 weighted spin-echo scans were initially acquired (TR: 4000 ms, TE: 48 ms, FOV: 2 cm, 
matrix size 256 x 256, NEX: 6, slice thickness: 0.5mm, number of slices 15, coronal 
sectioning). T1 weighted spin-echo scans prior to and 10 minutes after subcutaneous injection 
of 0.1 mL Omniscan contrast agent were then aquired (TR: 1000 ms, TE: 9 ms, FOV: 2 cm, 




Animals were sacrificed when their wellbeing was considered an issue (according to animal 
facility check-list), in this study all mice were sacrificed after the 2nd mouse had had to be 
euthanized. The first two mice to be sacrificed had developed tail necrosis, probably due to 
prolonged injection through the tail-vein. 
Animals were sacrificed using a CO2 gas inhalation system, and the brains of 4 of the mice 
were collected for histology. 
 
3.2.3.4 Histology  
In order to evaluate tumor burden for two representative animals (1 of each group) and to 
compare tumor burden after endpoint with BLI and MRI data, histological examination of two 
brains were carried out. The brains of the mice were harvested shortly exceeding time of 
death, and fixated in a solution of 2.5 % paraformaldehyde in PBS. 
After fixation brains were dehydrated in 70 % EtOH, embedded in Gurr paraffin wax, and 
sliced in coronal orientation to a thickness of 5 µm slices, using a Leica RM2155 microtome, 
at 3 levels with 1 mm distance between, and placed upon microscopy slides.   
Hematoxylin and Eosin (H&E) Staining: 
The sections were treated in subsequent baths with xylene 2x4 minutes, 2x3 minutes in 100 % 
EtOH, 2x3 minutes in 96 % EtOH, 3minutes in 70 % EtOH, 3 minutes in distilled water, 45 
seconds in Hematoxylin dye, 10 minutes in running tap water, 3minutes in 70 % EtOH, 
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3minutes in 96 % EtOH, 20 seconds in Eosin dye, dipped in 2x100 % EtOH baths, 2x5 
minutes in xylene. After which cover slides were glued onto the stained samples.  





Inkscape™v0.091, open-source vector graphics program, distributed by incscape.org was 
used in assembling and labeling images into figures. 
ImageJ v1.50b open-source image processing program, distributed by the National Institute 
for Health (Bethesda, Maryland, USA) was used to analyze time-lapse microscopy image 
series [76]. 
ITK-SNAP v3.4.0-rc1 open-source medical imaging analysis software, distributed by 
itksnap.org, developed at University of Pennsylvania and University of Utah, USA, was used 
for viewing and analyzing MRI images. 
NIS-Elements viewer v4.20.00 provided by NIKON (Tokyo, Japan) was used for microcopy 
image viewing, file-conversion, and adding scale-bars. 
GraphPad PRISM v6.04 by GraphPad Inc. (San Diego, CA, USA) was used for making 
quantitative analyses and graphs thereof. 
NordicICE v4.04 by NordicNeuroLab, Bergen, Norway, was used for DCE-MRI analysis, 
i.e. calculating A.U.C. and Ktrans values. 
Excel 2013 by Microsoft® (Seattle, USA) as part of Office© suite was used for parts of data 
analyses. 
Word 2013 by Microsoft® (Seattle, USA) used as primary text editor. 







4.1 In vitro 
4.1.1 Vemurafenib cell culture experiments 
4.1.1.1 Cell Viability assay 
Cell viability was assessed using a resazurin-resorfin viability assay, showing concentration 
dependent growth/proliferation inhibition of the H1_DL2 melanoma derived cell line when 
treated with vemurafenib. Furthermore the IC50 values for H1_DL2 cell line cells were on 
average an order of magnitude lower than for those of human fibroblast cell line SV80, 
6.47*10-7 vs. 1.74*10-5 M vemurafenib (Figures 4.1 & 4.2). 
 
Figure 4.1: Cell Viability assay. Resazurin cell survival assay of H1_DL2 melanoma cell line treated with 










4.1.1.2 Light microscopy 
Conventional brightfield microcopy was performed on H1_DL2 melanoma cell line cells 
treated with 50µM vemurafenib and untreated control cells, to assess morphological 
differences of cells treated with vemurafenib compared to untreated controls (Figure 4.3). The 
cells treated with vemurafenib showed visibly less growth, as also confirmed by resazurin-
resorfin viability assay, as well as a more elongated spindle-like phenotype compared to the 
untreated controls. The effects of vemurafenib upon the cells were enduring (96 hours) 
showing inhibition of cell growth and proliferation. 
 
 
Figure 4.3: Cell morphology of H1_DL2 cells treated with 50 µM vemurafenib (bottom row) after 24 hours 
48 hours and 96 hours, compared to untreated cells (top row). A more spindly appearance was observed in the 
treated cells, as well as visibly fewer cells in each treated well. In images of cells treated with 50 µM 
vemurafenib crystalline precipitations could be observed, which are vemurafenib precipitating in an aqueous 
solution. Microscopy images taken with Nikon TE2000, magnification X10. Scale bar = 125 µm. 
 
4.1.2 K16ApoE cell culture experiments 
4.1.2.1 Survival assay 
In order to assess the cytotoxicity of K16ApoE, resazurin-resorfin viability assays were 
performed on a selection of cell-lines, in which viability was measured after 45 minutes of 




Figure 4.4: Relative survival of MDCKII canine kidney endothelial cell line treated with varying 
concentrations of K16ApoE (0.1 , 1 , 20 , 40 , 60 , 80 , 100 & 150 µg/ml) as determined by a resazurin 
viability assay. Concentrations in graph are in Molar. 
 
MDCKII cells treated with K16ApoE showed a concentration dependent decrease in survival, 
with an averaged IC50 of 7.115*10
-6M K16ApoE (Figure 4.4). The peptide did not affect cell 
survival measurably at concentrations around 4 µM or below. 
 
Figure 4.5: Relative survival of RBE4 rat brain endothelial cell line treated with varying concentrations of 
K16ApoE (0.1 , 1 , 20 , 40 , 60 , 80 , 100 & 150 µg/ml) as determined by a resazurin viability assay. 
Concentrations shown in Molar on graph. 
 
RBE4 cells treated with K16ApoE showed a concentration dependent decrease in survival, 
with an averaged IC50 of 6.637*10
-6M K16ApoE (Figure 4.5). The peptide did not affect cell 
survival measurably at concentrations around 4 µM or below. 
 
Figure 4.6: Relative survival of H1_DL2 melanoma cell line treated with varying concentrations of K16ApoE 
(0.1 , 1 , 20 , 40 , 60 , 80 , 100 & 150 µg/ml) as determined by a resazurin viability assay. Concentrations in 




H1_DL2 cells treated with K16ApoE showed a concentration dependent decrease in survival, 
with an averaged IC50 of 5.714*10
-6M K16ApoE (Figure 4.6). The peptide did not affect cell 
survival measurably at concentrations around 4 µM or below. 
In summary there were no obvious differences in cell viability between the three cell lines that 
were tested. 
 
4.1.2.2 Time-lapse Fluorescence Microscopy 
The viability studies showed that K16ApoE doses of up to around 4 µM did not affect cell 
viability. However, higher doses were shown to be toxic to the cells. Based on the previous 
viability studies, we picked peptide doses around the IC90 dose (80 and 100 µg/mL). In order 
to assess membrane stability, time-lapse fluorescent microscopy was performed on cells with 
cytoplasmic fluorophores, treated with K16ApoE (Figure 4.7). 
 
Figure 4.7: Frames from time-lapse microscopy of MDCKII transduced with mcherry and treated with 
K16ApoE. A) Untreated control cells 0 minutes. B) Untreated control cells 30 minutes. C) Untreated control 
cells 60 minutes, D) Cells treated with 100 µg/mL K16ApoE 0 minutes. E) Cells treated with 100 µg/mL 
K16ApoE 30 minutes. F) Cells treated with 100 µg/mL K16ApoE 60 minutes. Images are taken in the red-
channel, using the NIKON TE2000 microscope and the NIKON NIS elements acquisition software. Scale bar 






Figure 4.8: Binary images created from fluorescence timelapse acquisition images of MDCKII mcherry cells 
treated with K16ApoE. A) Untreated control cells at 0 minutes, B) Untreated control cells at 30 minutes, C) 
Untreated control cells at 60 minutes. D) Cells treated with 100 µg/mL K16ApoE at 0 minutes, E) Cells 
treated with 100 µg/mL K16ApoE at 30 minutes, F) Cells treated with 100 µg/mL K16ApoE at 60 minutes. 






Figure 4.9: Time-lapse microscopy curves of mcherry intensity of MDCKII cells treated with varying 
concentrations of K16ApoE. Cells were either untreated (top curve) or treated with 80 µg/mL K16ApoE 
(middle curve) or 100 µg/mL K16ApoE (bottom curve). The curves show percentage of fluorescence relative 
to initial fluorescence (defined as 100 %). CTR denotes untreated controls. Microscopy was done on the 
NIKON TE2000 light, & fluorescence microscope. Change in fluorescence interpreted as area covered by 
fluorescing cells, the segmentation was done in ImageJ using Otsu’s method. 
 
Time-lapse microscopy of MDCKII cells (Figures 4.7, 4.8 and 4.9) transduced with mcherry 
red fluorescent protein, and treated with K16ApoE, showed a decrease in fluorescence, 
compared to negative (untreated) control. The fluorescence intensity dropped to around 65 % 
after treatment with 80 µg/mL K16ApoE and to 55 % after treatment with 100 µg/mL 




Time-lapse microscopy of H1_DL2 cells, which are transduced with GFP, did not show clear 
changes in fluorescence when treated with 80 and 100 µg/mL, relative to the negative controls 
(data not shown). 
 
4.1.2.3 Electron Microscopy 
To assess detailed morphological differences and investigate cell-cell contacts at peptide 
concentrations around the IC90 doses, electron microscopy of epithelial cell lines treated with 
concentrations 20, 40, 80 µg/mL relative to untreated controls of confluent cells in monolayer, 
was performed. 
 
Scanning Electron Microscopy 
 
 
Figure 4.10: Scanning electron microscopy of MDCKII cell line monolayer cells treated with varying 
concentrations of K16ApoE. A, E) control series, B, F) 20µg/ml K16ApoE, C, G) 40µg/ml K16ApoE, D ,H) 
80µg/ml K16ApoE. A-D Scale bar = 30µm, E-H Scale bar = 4µm. Acquisitions were made using the Jeol 
JSM-7400F Scanning Electron Microscope. 
 
MDCKII cells grown to confluence and treated with varying concentrations of K16ApoE (0, 
20, 40, 80 µg/mL), showed a concentration dependent increase in aberrant and dying cells, 
dissociating from the monolayer. (Table 4.1 and Figure 4.10) The number of aberrant and 
dying cells were significantly higher in all treated groups (p<3*10-5). The difference in 
number of dying cells between those treated with 80 µg/mL compared to those treated with 20 
µg/mL was significant (p<0.05), whilst the difference between 40 and 80 µg/mL was not 




Table 4.1: Average number (from 5 parallels)of abnormal/ dying MDCKII cells visible in SEM images at 
400X magnification, at different concentrations of K16ApoE treatment, relative to untreated control cells. 
SD=standard deviations. P-values < 3.3*10-5 all treated relative to control series. P-values: 80vs20 µg/ml: 




Abnormal/Dying cells SD 
80 75 24,45 
40 50 14,15 
20 40 7,7 
0 1 0,45 
 
 
The differences in number of aberrant/dying cells quantified (Table 4.1, Figure 4.11) can 
readily be observed from SEM images of cells treated with varying concentrations (20, 40, 80 
µg/mL) relative to untreated controls at magnification 400x (Figure 4.10: A-D). Differences 
in cell surfaces could clearly be seen on images of cells at 3000X magnification, with tears in 
the monolayer more apparent at higher concentrations of K16ApoE (Figure 4.10: E-H & 
Figure 4.11). 
 
Figure 4.11: Number of aberrant and dying cells counted on SEM images of MDCKII cells treated with 0, 
20, 40, 80 µg/mL K16ApoE. p-values from two sided student t-test between concentrations. (* = p < 0.05, ** 




Transmission Electron Microscopy 
 
 
Figur 4.12: Transmission electron microscopy images of MDCKII cells treated with 0 and 80 µg/mL 
K16ApoE for 45 minutes. A) Control cells, scalebar=7µm. B) Control cells, scalebar=500nm. C) Control 
cells, scalebar=200nm. D) Cells treated with 80 µg/mL K16ApoE, scalebar=7µm. E) Cells treated with 80 
µg/mL K16ApoE, scalebar=500nm. F) Cells treated with 80 µg/mL K16ApoE, scalebar=200nm. Arrows 
indicate cellular junctions, presumably desmosomes. 
 
Transmission electron microscopy of MDCKII cells (Figure 4.12), showed no readily 
observable difference between controls or cells treated with the highest concentration (80 
µg/mL) of K16ApoE. Cell-junctions were observable and intact for both treated and untreated 







4.2 In Vivo 
4.2.1 K16ApoE Kinetics: DCE-MRI 
DCE-MRI was performed on healthy NOD-SCID mice in order to independently verify 
previously published results [51, 52, 77, 78], and evaluate the duration of BBB opening in the 
model system. Gadodiamide (Omniscan®) having a MW of 573.66 did not cross over an 
intact BBB, and was therefore deemed effective in assessing BBB permeability to large 
molecules. 
4.2.1.1 K16ApoE effect on BBB 10 minutes post administration 
 
 
Figure 4.13: DCE-MRI 200 µg K16ApoE 10 minutes: Area under curve (AUC) and volume transfer 
coefficient K1,2 maps for mice treated with 200µg K16ApoE compared to negative controls (injected with 
saline). 10mK16=10 minutes post i.v. injection of K16ApoE, 10mNC=10 minutes post saline i.v. (Negative 
Control). Analyses preformed with NordicIce v4.04. 
 
DCE-MRI of animals performed 10 minutes after administration of 200 µg K16ApoE, 
showed an increased uptake of contrast fluid into the brain, relative to control animals given a 
saline infusion 10 minutes prior to DCE-MRI (Figure 4.13). 
Table 4.2: Area under curve (AUC) and volume transfer coefficient (K1,2) values for animals injected with 
200 µg K16ApoE 10 minutes post injection, and corresponding negative controls (NC). SD denotes standard 
deviations. Values from a region of interest encompassing most of the brain, A = 65.6±0.2 mm2. 
K16ApoE     NC    
AUC SD K12 SD  AUC SD K12 SD 
1680540 384321 0,07 0,025  202900 160057 0,008 0,02 
3580780 599486 0,1384 0,0553  183117 164821 0,007 0,15 





Quantification of area under curve values and volume transfer coefficient K1,2 (Table 4.2) for 
a region of interest encompassing most of the brain, (area = 65.6±0.2 mm2), also confirmed 
this. P-values<0.05 for AUC relative to controls and K1,2 relative to controls. 
 
4.2.1.2 Evaluation of duration of BBB opening after injection of K16ApoE 
 
 
Figure 4.14: DCE-MRI 200 µg K16ApoE 10 minutes – 4hours: Area under curve and volume transfer 
coefficient K1,2 maps for mice treated with 200 µg of K16ApoE at time-points: 10 minutes, 30 minutes, 1 
hour, 2 hours, 4 hours post i.v. injection. NC denotes negative control, shown for a mouse injected 10 minutes 
prior to DCE. Analyses preformed with nordicIce v 4.04. Data for 1 hour K16ApoE from scans performed by; 
Olivier Keunen, Frits Thorsen and Heidi Espedal. 
 
The uptake of contrast fluid decreased with time as can be seen from AUC and K1,2 maps of 






Figure 4.15: Area under curve (AUC) values for animals injected with 200 µg K16ApoE, at varying time-
points post injection; 10 minutes (10mk16), 30 minutes (30mk16), 1 hour (1hk16*), 2 hours (2hk16), 4 hours 
(4hk16) and negative controls (NC).  n = 3, 2, 4, 1, 5, 11 respectively, error-bars show standard deviations. 
Values from a region of interest encompassing most of the brain, (area = 65.6±0.2 mm2). *Data for 1 hour 




Figure 4.16: K1,2 (volume transfer coefficient) values for animals treated with 200 µg K16ApoE at varying 
time-points post injection; 10 minutes (10mk16), 30 minutes (30mk16), 1 hour (1hk16*), 2 hours (2hk16), 4 
hours (4hk16) and negative controls (NC).  n = 3, 2, 4, 1, 5, 11 respectively, error-bars show standard 
deviations. Values from a region of interest encompassing most of the brain, (area = 65.6±0.2 mm2). *Data for 





























Negative controls were found not to be different, whether saline injection given at 10 minutes 
4 hours, or any time-point in between, prior to scan, and thus combined to form a single 
group. 
Quantification of AUC and K1,2 values (Figures 4.15 and 4.16) from a region of interest 
encompassing most of the brain, (area = 65.6±0.2 mm2) both showed a decrease towards 
baseline at 4 hours post administration. Differences in A.U.C values were significant to 
p<0.05 between (time after injection of K16ApoE): 10 minutes and controls, 10 minutes and 4 
hours, 30 minutes and negative controls, 30 minutes and 4 hours, 1 hour and negative 
controls, 1 hour and 4 hours. Other p-values between A.U.C groups were: 10 minutes and 30 
minutes; p=0.53, 10 minutes and 1 hour; p=0.13, 30 minutes and 1 hour; p=0.29. Differences 
in K1,2 values were significant to p<0.05 between (time after injection of K16ApoE): 10 
minutes and negative control, 10 minutes and 1 hour, 10 minutes and 4 hours, 30 minutes and 
negative control, 30 minutes and 4 hours, 1 hour and negative control, 1 hour and 4 hours. 
Other p-values between K1,2 values were: 10 minutes and 30 minutes; p=0.12, 30 minutes and 
1 hour; p=0.66. P-values from two tailed student t-test. The 2 hour time-point, due to time-
constraints, had only one animal, therefore a t-test could not be performed. 
 
4.2.1.3 Half-dose (100 µg K16ApoE) experiments 
 
 
Figure 4.17: DCE-MRI 100 µg K16ApoE 10 minutes: Area under curve and volume transfer coefficient K1,2 
maps for mice treated with 100 µg of K16ApoE 10 minutes post injection, compared to negative controls, 






Figure 4.18: Area under curve values for 200 µg, 100 µg K16ApoE and control. AUC values from series 10 
minutes after injection of peptide. Values from a region of interest encompassing most of the brain, (area = 
65.6±0.2 mm2).  Error bars show standard deviations. n=3, 3, 11 respectively. 
 
 
Figure 4.19: K1,2 (volume transfer coefficient) values for 200 µg, 100 µg K16ApoE and control. K1,2 values 
from series 10 minutes after injection of peptide. Values from a region of interest encompassing most of the 
brain, (area = 65.6±0.2 mm2).  Error bars show standard deviations. n=3, 3, 11 respectively. 
 
The average AUC value for animals administered 100 µg/ animal (AUC and K1,2 maps seen 
in Figure 4.17) was 710880 with a standard deviation of 194597, and the K1,2 value 0.021 
with a standard deviation of 0.0031. A two tailed student t-test gave p-values of p<2*10-6 for 
AUC values relative to negative controls, and p=0.12 for K1,2 values relative to negative 




























saline 10 minutes prior to scan, were not significantly different from saline injections of 100 
µL 10 minutes prior to scan. P-values: 0.79 and 0.84 respectively. 
Comparison between animals given 200 µg of K16ApoE and those given 100 µg K16ApoE 
(half-dose) for scans done 10 minutes after injections, showed halving the dose reduced 
average AUC values to 27 % of those for 200 µg K16ApoE, and average K1,2 values to 38 % 
of those for 200 µg K16ApoE (Figures 4.18 and 4.19).  
 
4.2.1.4 Intra peritoneal administration of K16ApoE 
A scan was also done to evaluate IP administration of K16ApoE. A dose of 300 µg of 
K16ApoE was administered intraperitoneally 30 minutes prior to DCE-MRI. AUC and K1,2 
values were indistinguishable from negative controls (data not shown).  
 
 
4.2.2 Pilot Study: Combinatorial Treatment of xenografted melanoma with vemurafenib and 
K16ApoE 
The pilot study was performed in order to assess the clinical relevance of K16ApoE to brain-
metastatic melanoma. Vemurafenib which on its own is too large to bypass an intact BBB 
(MW 489.92 Da), was co-administered with the BBB-permeabilizing agent K16ApoE. This 
was done in order to determine if the combinatorial treatment approach could improve 
survival and affect tumor burden. 
 
4.2.2.1 Animal weight over time 
Weight of the animals was measured continuously throughout the pilot, as an indicator of 




Figure 4.20: Weight of mice in pilot treatment study compared to days post intracardial injection of tumor 
cells. Treatment commenced at day 9 post intracardial injection. V+K16=vemurafenib+K16ApoE, 
V=vemurafenib alone. 
 
The weights of the animals declined time, without showing any clear trend favoring either 
group, K16ApoE+vemurafenib or vemurafenib alone (Figure 4.20). 
 
4.2.2.2 BLI 
BLI was performed to assess tumor burden of the animals at 4 weeks post-injection of tumor 
cells. 
 
Figure 4.21: BLI images of two mice from the pilot study. A) Supine position of- mouse from the group 
treated with both K16ApoE and vemurafenib, B) prone position of- mouse from the group treated with both 
K16ApoE and vemurafenib. C) Supine position of- mouse from the group treated with only vemurafenib, D) 
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There was a tendency that the BLI intensities were lower (or the same for supine brain) in the 
animals treated with both K16ApoE and vemurafenib, compared to those treated with 
vemurafenib alone. However the averaged BLI-values were not statistically significantly 
different from one another with all p-values>0.3 (supine body: p=0.3668, supine brain: 




Figure 4.22: Integrated ROI intensities from BLI. K16&Vem.= the group treated with both K16ApoE and 
vemurafenib, Vem. = the group treated with only vemurafenib. p-values from two sided student t-test between 









4.2.2.3 Anatomical MRI 
At week 5 post tumor-cell injection, anatomical MRI was performed to assess the number of 
brain-tumors and total tumor volumes for the animals. Three sequences were used: T1,T2, T1 
with contrast enhancement, contrast-enhancement here refers to contrast enhancement by 
subcutaneous injection of 0.1 mL of Omniscan® (Gd-diamide) contrast agent (Figure 4.23). 
 
Figure 4.23: Anatomical MRI images taken at week five post injection of tumor cells. A, B, C: T1, T2, T1 
with contrast enhancement of female treated with both vemurafenib and k16ApoE. D, E, F: T1, T2, T1 with 
contrast enhancement of female treated only with vemurafenib. Contrast enhancement refers to administration 
of 0.1ml subcutaneous Omniscan® contrast-fluid. Viewfield = 2 x 2 cm. 
 
 
Table 4.3: Tumor count and estimated total tumor volumes from anatomical MRI images, mice treated 
with vemurafenib and K16ApoE are called “Vem.+K16”, mice treated with vemurafenib alone are called 
“Vem. only”. Treated and untreated groups are not significantly different, student t-test gives p-values: 
0.293 for number of tumors 0.242 for tumor volumes. The analysis done in the ITK-SNAP Toolbox © 
segmentation software v3.4. 
 
    TUMOR COUNT   
TUMOR VOL. 
mm3   
  
Average 
Vem.+K16 71±13   2.17 ±0.22   
            
  
Average Vem. 
Only 101.5±42   4.02±2.39   






In general, there was a trend towards reduced number of tumors as well as reduced total tumor 
volume after combined treatment with K16ApoE and vemurafenib. Mice treated with only 
vemurafenib had on average more tumors (number) and larger tumors than those that received 
vemurafenib and K16ApoE. (Table4.3, Figures 4.23 and 4.24) The number of tumors in the 
vemurafenib only group were 101±42 tumors compared to the K16ApoE and vemurafenib 
group with 71±13 tumors. Total tumor volume in vemurafenib only group were on average 
4.02 mm3 compared to 2.17 mm3 in the vemurafenib and K16ApoE group. However the 
differences were not statistically significant (p=0.293 for the number of tumors and p=0.242 
for tumor volumes). 
 
 
Figure 4.24: Tumor count and volumes averaged for group treated with both K16ApoE and vemurafenib 
(K16&Vem.) and the group treated with only vemurafenib (Vem. only). A) Average total number of 
intracranial tumors. B) Average total tumor-volume of observed tumors. p-values from two sided student t-













To assess tumor burden after endpoint, and to compare to anatomical MRI data taken 




Figure 4.25: Tumors identified in histological slides, H&E stained 5 µm thick slices of two mouse brains 
from pilot experiment, A-D are from a mouse treated with both vemurafenib and K16ApoE, E-H are from a 




As was seen in MRI data (Figure 4.21), tumors were readily observable in histological slides 
of the brains of the mice (Figures 4.25 and 4.26); done on one from each group. Tumors were 
both large and small, as well as numerous in both mice, with some being of a size likely 
below MRI detection limits. Visual inspection of slides indicates somewhat greater tumor-
burden for the mouse treated with only vemurafenib, compared to the one treated with both 






Figure 4.26: Histological sections of the brains of mice from pilot study, of one mouse from the group treated 
with K16ApoE and Vemurafenib (K16&Vem.) and one from the group treated with only Vemurafenib (Vem. 
only), both female mice. Arrows indicate tumors, (there are more tumors than indicated with arrows). Brains 
were sectioned 5 µm thick, at three depths, 1 mm apart, slice level is indicated by numbers 1-3. Images taken 
using large image acquisition mode on the NIKON TE2000 microscope and NIS Elements acquisition 

















Brain metastasis is a common and serious complication arising in up to 40 % of cancer 
patients [31]. The most common causes of brain metastasis are: lung cancer (50 %), breast 
cancer (20 %), melanoma (10 %) and colon cancer (5 %). As of today there are few treatment 
options, besides surgery, chemotherapy and radiotherapy [32]. Even improved treatment 
regimens such as those including stereotactic radiosurgery (SRS) only briefly extend survival. 
The prognosis of patients diagnosed with brain metastasis is extremely poor, with mean 
survival under treatment at only 9-10 months, despite extensive treatment [31]. 
Malignant melanomas, have commonly been treated with systemic chemotherapy in addition 
to surgery, but this has been of limited success [11].  Novel treatments have arisen in recent 
years, with targeting of signaling kinases with specifically tailored inhibitors (e.g. 
vemurafenib) [21], or using monoclonal antibodies [24, 25], for immune response mediated 
action (e.g. Ipilimumab, Pembrolizumab and Nivolumab) [26]. 
A major problem in treating brain metastases with chemotherapy is that for early stages and 
small tumors the blood brain barrier (BBB) remains closed, effectively protecting the tumors 
from many chemotherapeutic agents [33]. An intact BBB is largely impermeable to large and 
hydrophilic molecules greatly limiting which chemotherapeutics can be used in early brain 
metastatic development [40]. The problem of the intact BBB excluding treatments has been a 
field of interest for quite some time, and several strategies to disrupt or circumvent the BBB 
have been explored. The use of focused ultrasound guided by MRI for localized BBB 
permeabilization has shown promise and is currently under clinical safety evaluation [45, 79, 
80]. Hypertonic solutions (e.g. urea, arabinose, mannitol, etc.) have been shown to induce cell 
shrinkage at the BBB, allowing penetration of compounds normally too large to cross into the 
brain parenchyma [49]. Certain solvents such as DMSO, ethanol and glycerol have also been 
shown to permeabilize the BBB, though when used at very high doses [43]. 
The existence of so few viable strategies lead to the development of a peptide at the center of 
this study, using the receptor binding domain of ApolipoproteinE with a 16 Lysine tail, and a 
BBB permeabilizing construct was thus made made [52]. K16ApoE was shown to affect the 
BBB in rats when co-administered with Evans blue dye, which normally does not cross the 
intact BBB. A significant increase in uptake of Evans blue was demonstrated, and this novel 
peptide showed promise in getting chemotherapeutics into the brain [51].   
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The aim of my thesis was thus to elucidate more on the biology of this newly developed 
peptide. My study was intended to examine by MRI if K16ApoE was capable of opening the 
BBB also in mice, how early this effect could be detected after administration and how long 
the BBB remained open. By using DCE-MRI, we were able to show that the BBB was 
permeabilized from 10 minutes up to at least 2 hours after intravenous administration of 
K16ApoE in mice. These results are promising as to allow for penetrance of therapeutics 
which would normally not enter the brain parenchyma (or only enter on a limited scale), and 
thereby increasing treatment efficacy of these drugs. 
 
Prior to performing a pilot study of combined treatment with K16ApoE and vemurafenib (a 
drug targeting BRAFV600E mutated melanoma) in vivo, we needed to establish whether 
vemurafenib also was effective in treating human melanoma brain metastasis cell lines. 
This was first studied in cell culture. Vemurafenib decreased cell-survival in a concentration 
dependent manner, with IC50 far lower in BRAF
V600E mutated melanoma cells, compared to 
wild type cells. 
Vemurafenib has previously been shown to preferentially act upon BRAF mutated melanoma 
cells with the V600E mutation and also the V600K mutation. These mutations are activating 
mutations of the BRAF kinase, promoting growth and proliferation via the MAPK/ERK 
pathway [21]. This treatment effect is achieved by the design of this enzyme inhibitor, which 
gives it a higher degree of complementarity towards the V600E mutated kinase [81]. The 
prevalence of this mutation is high in melanomas, while also occurring in other cancers [82]. 
Thus vemurafenib is, as intended, a valid therapeutic agent for the treatment of metastatic 
melanoma. Our study also showed that the drug was effective in treating melanoma brain 
metastatic cells. 
 
The light microscopy study of H1_DL2 melanoma brain metastasis cells treated with 
vemurafenib showed a change in phenotype and decreased growth relative to untreated 
controls. 
Cells treated with vemurafenib exhibited growth inhibition but little cell death, and not a 
complete inhibition of growth, meaning that vemurafenib only inhibited tumor cell 
development temporarily and incompletely. Previous clinical studies have shown that after an 
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initial treatment response melanomas develop resistance, by activating MAPK/ERK 
downstream of BRAF. The development of resistance thus limits the efficacy of vemurafenib. 
In the clinic combined treatment and specialized dosing regimens are used to try to forestall 
and avoid resistance [23]. Observations done in this study seem to coincide with what was 
already reported in the literature.  
 
We next wanted to elucidate on the mechanisms of action of the peptide on endothelial cells, 
which are the first cells that circulating K16ApoE will meet in the bloodstream. Doses of up 
to around 4 µM did not show reduced cell viabilities. The results showed that higher doses of 
peptide exerted its effect by direct cell cytotoxicity.  
The high unspecific cytotoxicity of the peptide, demonstrated that caution has to be taken in a 
clinical setting, in order to avoid permanent damage to endothelial cells with subsequent 
organ damage.  
It should be noted that viability assays such as the one used in this study do not directly 
measure cytotoxicity. Viability assays measure cell-viability, i.e. cell cycle or cell growth 
arrest would influence such an assay [83]. 
The group of Professor Catharina Davies at NTNU also concurrently working on K16ApoE, 
found that cells die at comparable doses as those in this study. Cell culture studies done by 
PhD student Synnøve Nymark Aasen in our lab, using the live-dead staining kit, also 
confirmed cytotoxicity in this concentration range. Of note is that in the in vitro experiments 
in this study, cells were kept in high doses of K16ApoE for prolonged periods of time (45 
minutes and longer), which does not compare to the in vivo setting where the peptide will 
rapidly wash out of the system, in a matter of minutes. The in vivo situation might thus be 
better understood as a transient high dose. It is therefore likely that the cytotoxicity seen in the 
cell culture experiments would be largely diminished. A subacute toxicity study done by 
Sarkar et al. did not show any lasting effects in the animals, with histopathological 
examination not showing any organ damages [78]. 
 
Time-lapse fluorescence microscopy showed decrease in cytoplasmic fluorescence in cells 
treated with K16ApoE, indicating cell membrane disruption. 
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Time-lapse demonstrated that the cell membranes were damaged by the peptide at high 
concentrations, with leakage of internal components from the cells. The peptide is here 
indicated to act in a lytic fashion, rapidly killing cells through what may be induced 
membrane damage.  
The peptide K16ApoE was designed to constitute the LDL-receptor binding domain of 
ApolipoproteinE [52], suggesting that the mode of action  takes place at the cellular 
membrane. The peptide is basic, with a charge of 24 (calculated). The cell membranes are 
negatively charged, which may allow for this peptide to more readily attach to these, and 
inducing a lytic effect.  Lower concentrations of the peptide are however expected to induce 
receptormediated endocytosis, with far less lysis. Unpublished results from Davies group at 
NTNU, have shown clathrin mediated cellular uptake by flow cytometry. 
Whether K16ApoE only acts on the LDLR, or can bind to other targets is not currently 
known. The mode of action in vivo was found to coincide with higher tissue expression levels 
of the LDLR, which was taken as evidence of K16ApoE acting via the LDLR [52]. The 
specificity of the design suggests that a LDLR mediated mechanism may somehow be 
involved in the cytotoxicity of the peptide. The time-lapse experiment showed membrane 
leakage almost immediately, suggesting rapid onset of this (membrane disruptive) effect, and 
further suggesting this might also be the case in vivo, where there is a transient high dose of 
the peptide which is washed out rapidly compared to the in vitro experiments.  
 
Scanning electron microscopy showed damaged and dying cells and disruption of a confluent 
monolayer of cells treated with high doses of K16ApoE.  
The cytotoxicity of K16ApoE was confirmed again by SEM, strongly suggesting that 
K16ApoE BBB permeabilization at high doses is of a cytotoxic nature. This implies that 
damages to the elsewise confluent monolayer of brain vasculature endothelium, is a large part 
of the BBB permeabilizing effect of K16ApoE. The disruptive effect on a confluent cell 
monolayer was also found by Catharina Davies group at NTNU, who concluded that this 
leads to increased transport over the endothelial cell barrier (unpublished results). Given such 
a mode of action, finding ways to limit the dose, and exposure of unrelated organs to 
K16ApoE may be prudent. More localized administration and possibly targeted delivery via 
for example focused ultrasound and microbubbles [47] could be a possibility, which has 
already been proposed for harm reduction in chemotherapeutic agent delivery. The cells in the 
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in vitro experiments were kept for prolonged periods in solutions containing high doses of 
K16ApoE, which may not accurately describe the effects in vivo, where the peptide would 
also continuously be washed out. 
 
Transmission electron microscopy showed no disruption of cell-cell junctions in cells treated 
with K16ApoE relative to untreated controls. 
K16ApoE does not act on cell-cell adhesion molecules, altogether eliminating one possible 
mechanism of action. The cells did not lose adherence until dying, and cell-cell junctions 
remained intact. This is consistent with what was found by the group of Catherina Davies at 
NTNU, where apart from dead cells dissociating from the intact monolayers, the monolayers 
remained unchanged (unpublished results). The remaining candidates for mode of action are 
thus: cytotoxicity, wherein dying cells leave openings in a cell monolayer, such as the BBB, 
and receptor mediated endocytosis, for which there has been found some evidence by 
Catharina Davies et al. (clathrin mediated endocytosis was observed in vitro). 
 
DCE-MRI of mice after intravenous administration of 200 µg K16ApoE showed opening of 
BBB already 10 minutes after injection. The administered dose in the animals was initially 
high, approximately 100-125 µg/mL peptide in the total blood volume (estimated to be around 
1.5-2 mL in a mouse). However similar types of peptides have been noted to wash out rapidly 
in vivo (in mice) over the course of minutes [84]. The previously noted wash-out effect was 
likely also the case in our study, thought to quickly diminish the blood concentration of 
K16ApoE limiting the cytotoxic effects observed in the cell culture studies on high doses. 
As found by Sarkar et al. [52, 77, 78, 85] K16ApoE opens the BBB, when given as a slow 
infusion at a dose of 200 µg per animal. Quantification of signal change in DCE-MRI 
confirmed what Sarkar et al. showed with Evans Blue Dye in mice, as well as various 
chemotherapeutic compounds [51, 78], that comparably large molecules can cross over the 
BBB if given in concert with K16ApoE. 
 
DCE-MRI of mice treated with 200 µg K16ApoE showed a decrease in the degree of BBB 
permeabilization over time, with mice at 4 hours after injection of K16ApoE being 
indiscernible from control animals. 
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The BBB rapidly regenerated after injections of K16ApoE, as also found by Sarkar and 
colleagues [51], indicating K16ApoE may be given continuously for extended periods of 
time, without permanent damages to the BBB. Neither Sarkar et al. or our group noticed any 
impairment to animals given repeated administrations of K16ApoE. Subacute toxicity studies 
done by previously did not show damaging effects on mice given repeated doses of K16ApoE 
[78]. The regeneration of the BBB after injections of K16ApoE, even in mice that have 
previously been given the peptide, shows promise in that the peptide may be safely applied 
clinically. The regeneration of the BBB also places a time limit on co-administration of 
therapeutics, after 4 hours the BBB in mice did recover completely and large compounds can 
therefore no longer gain access to the brain parenchyma after this time point. 
 
Due to the cytotoxic effect of high doses of K16ApoE observed in vitro, we wanted to see if 
lowered doses of K16ApoE could open the BBB as effectively. DCE-MRI of mice treated 
with 100 µg K16ApoE also showed opening of BBB 10 minutes after injection of K16ApoE. 
The opening of the BBB by a dose of 100 µg per animal coincides with the findings of Sarkar 
and colleagues [51] who also noted a visible but decreased opening of the BBB. This shows 
that K16ApoE still mediates its effect on the BBB at this dosage, and the amount of contrast 
agent crossing over the BBB seemed to be reduced approximately by ¾. Being able to elicit 
an effect with a lower dose is of particular interest, given the non-specific and high toxicity of 
K16ApoE, yet a sufficient opening of the BBB would likely be achieved with a reduced dose. 
Taken into a clinical setting, cancer patients not tolerating the effects of K16ApoE well, or of 
initially poor health may thus still derive some benefit from the peptide when combined with 
chemotherapeutic drugs. This is particularly relevant as many cancer patients are elderly, and 
often in poor condition [86, 87].   
 
The pilot treatment study showed lower BLI intensities (at week 4) for, and a decrease in 
tumor size and total tumor volume measured by anatomical MRI (at week 5) for animals 
treated with both K16ApoE and vemurafenib relative to animals treated with only 
vemurafenib, although the differences were not statistically significant. 
Mice were treated from day 9 to week 5 after tumor cell injections. This time period is likely 
long enough for some of the tumors to develop treatment resistance [23]. The larger tumors 
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observed by MRI at week 5 also likely have a disrupted BBB, similar to what has been 
observed in previous studies [33]. Thus these tumors are not necessarily receiving a larger 
dose of drug due to opening of the BBB by the peptide, since the barrier is likely disrupted 
already. K16ApoE had previously been used in a treatment study of neurodegenerative 
lysosomal storage disease in a mouse model [78] where a therapeutic enzyme was delivered 
successfully over the BBB, and a treatment effect was observed. Also several other 
compounds have been found to move across the BBB after using the peptide [51, 52, 77]. 
Thus the results of our study suggest that K16ApoE can be applied to brain metastatic tumors, 
to open the BBB prior to administration of chemotherapeutic drugs which otherwise are not 
able to penetrate into the brain tissue. Based on the properties of the peptide, as described in 
our study there is reason to believe, that vemurafenib may cross over the BBB as our pilot 
study (with few animals) indicated a treatment effect when combining vemurafenib with the 
peptide. The dismal prognoses of brain metastatic cancer, and the current inability to treat 
early stages of brain metastases effectively [32], would make this strategy a welcome addition 
to therapeutic regimens.  
 
Future perspectives 
In parallel with this study, other in vitro experiments are currently being performed at NTNU 
in Trondheim, at the group of Catharina Davies, to elucidate more about the cellular 
mechanisms of K16ApoE (confocal studies to show membrane transport of K16ApoE). These 
studies are expected to elucidate more on the membrane action of K16ApoE. 
An in vivo bio-distribution study in mice tagging K16ApoE with 125I, to elucidate more on the 
organ uptake of K16ApoE, is being planned. This would also enable us to evaluate organ 
toxicity and if K16ApoE accumulates noticeably in certain organs. These experiments would 
serve as comparison to what Sarkar and colleagues have done, i.e. subacute toxicity studies, in 
which they found nothing of notice. 
Under work is a full-scale treatment study, wherein brain metastases are to be treated by 
combinatorial administration of K16ApoE and a chemotherapeutic agent, likely either 
vemurafenib or PLX4720, which is another BRAF inhibitor. Subsequent studies may also 
apply K16ApoE to the treatment of other brain metastatic cancers, such as lung, or breast 
cancer which commonly metastasize to the brain.  
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Depending on successes in full scale treatment studies, and preclinical safety evaluations, in 
time K16ApoE may move forward to clinical safety studies, and clinical studies. As of yet the 
peptide has only been evaluated in preclinical studies. K16ApoE is therefore still somewhat 
removed from clinical applications. The risk inherent in using K16ApoE, may conceivably 
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